Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis

Archives of Dermatology

Volumn 144, Issue 10, 2008, Pages 1403-1404

  Wu, Jia Jen ^b   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GLIMEPIRIDE; GLUCOSE; INFLIXIMAB; METFORMIN; METHOTREXATE; TUMOR NECROSIS FACTOR;

ADULT; CASE REPORT; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INJECTION SITE REACTION; LETTER; LIVER TOXICITY; MALE; MONOTHERAPY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; PSORIASIS; RECURRENCE; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54349108621     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.10.1403     Document Type: Letter

References (5)

1. Martínez-Abundis E, Reynoso-von Drateln C, Hernández- Salazar E, González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299(9):461-465.
2. Bonilla E, Lee YY, Phillips PE, Perl A. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis. 2007;66(12):1688.
3. Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-α for rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):178-179.
4. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(11):2606-2608.
5. Richez C, Blanco P, Gin H, Schaeverbeke T. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha. Clin Exp Rheumatol. 2006;24(5):607.